Stanford Diabetes Work-In-Progress Seminar Series
Participants: Members of Participating Stanford Research Groups.
Meeting Time: Every Friday, 12:00-1:00 pm.
Meeting Location: Beckman 302, Developmental Biology Library.
Each Friday, a different thematic group presents:
1st Friday: Pancreas and Islet Biology
2nd Friday: Bioengineering and Behavioral Sciences
3rd Friday: Metabolism and Signaling
4th Friday: Immunology and Islet Transplantation
Justin Annes MD PhD, Assistant Professor, Department of Medicine, Division of Endocrinology; Leader of the Enrichment Program for SDRC
Each session, held monthly, includes two speakers who provide a 20-25 minute discussion of their ongoing diabetes-related research. Presentation topics range from clinical research to basic science investigation, promoting a knowledge and collaboration between these spheres. The presentation format encourages questions and discussion both during and after each presentation. Presentations primarily focus on un-published work and as these meetings are intended to build new collaborations, share new insights (particularly new technologic innovations and how they might be applied) and facilitate new ideas/ research directions. Presenters and attendees include everyone from professors to undergraduate students. Thus this venue also aligns with our center’s training mission. Typical attendance is ~30-40 individuals per session. Snacks and drinks are provided to facilitate informal socializing and discussion following the presentations.
November 16th: CSB cutting edge lecture series: Dr Philip Scherer “Systemic Contributions of the Adipocyte in Diabetes, Obesity and Cancer”. Munzer Auditorium 12-1pm
November 9th: Dr. Latha Palaniappan: “Physical Activity Interventions in Type 2 Diabetes”
November 2nd: Andrew Posselt (Professor of Surgery and Director of Pancreatic Islet Program at UCSF): “Clinical islet transplantation, the UCSF experience”
Greg Szot (Core Manager, Islet Production Core at UCSF): “Pancreatic islet cell processing and cell therapy”
October 26th: Graham Barlow (Bollyky/Nolan labs): “Progression of Pancreatic and Immune Tissue Architecture During Type I Diabetes”
October 19th: Vivek Bhalla: “Role of Esm-1 as a Kidney-enriched Inhibitor of Leukocyte Infiltration and Albuminuria in Diabetic Nephropathy”
Baohui Xu (Dalman Lab): “Aortic aneurysm inhibition in diabetes”
October 12th: Cancelled due to ISPAD 2018 conference overlap
October 5th: Katja Pekrun(Kay lab):“DirectedEvolution of AAV for Islet Targeting”
Andrew Lipchik(Snyder lab): “Antibody-mediated inhibition of mitochondrial respiration as a predictor of insulin resistance”
September 28th: Jon Piganelli (Associate Professor, Children’s Hospital of Pittsburgh): Adaptive but Not Terminal UPR Induces Human β cell Immunogenicity: First Step in the Progression of β cell Destruction”
September 21st: Jiehan Li (Ingelsson lab): Genetic screening in adipocytes: combining CRISPR perturbations and single-cell RNA sequencing
Francois Haddad: Precision Initiatives in Diabetic Cardiomyopathy
September 14th: Peter Robinson: A new method for detecting antibody biomarkers in autoimmune diabetes
Molly Tanenbaum: Human factors as a pathway to improving diabetes care
September 7th: Gozde Durmus (Thakor lab): Levitating Pancreatic Tissues for Islet Transplantation
Kimberly Tsui (Bassik lab): Uncovering genetic modulators of Antibody-Drug Conjugate toxicity using CRISPR/Cas9 Screens
June 15th: Christopher Gardner: Recruitment Strategies for Trials – Lessons Learned, Resource Being Created
May 18th: Dr. Mohsen Fathzadeh (Knowles): The human lipodystrophy-like gene FAM13A affects fat distribution and function in mice
Dr. Katrin Svensson: Isthmin-1 is a hormone that regulates peripheral glucose homeostasis
May 11th: Dr. Eric Appel - Innovations in Insulin Formulation by Supramolecular Design
April 6th: Kyle Loh - Prospects for using human embryonic stem cells to treat diabetes: replacing the immune system or generating pancreatic progenitors?"
Hannah Moeller (Annes Lab) - Discovering Pathways Promoting Beta-Cell Identity and Function
March 23rd: Dr. Garrison Fathman - A novel approach to rejuvenate endogenous Treg function in the treatment of autoimmune diseases; can one drug treat all these diseases?
Discussion session led by the leaders
March 16th: Dr. Rick Kraemer - Cholesterol trafficking for steroidogenesis
Dr. Maurizio Morri (Ingelsson lab) – CRISPR-based high-throughput screening and validation of putative candidate genes for insulin resistance
March 9th: Event Cancelled
March 2nd: Event Cancelled
February 23rd: Dr. Jeffrey Liu (Roncarolo lab) - Engineering Tr1 cells to induce immune tolerance
Dr. Nadine Nagy - 4-methylumbelliferyl Glucuronide Inhibits Hyaluronan Synthesis and Promotes Foxp3+ Regulatory T-cell Induction
February 16th: Zahra Bahrami-Nejad (Teruel lab) - A core component of mature adipocytes enforces cell identity by mediating adipocyte differentiation
Dr. Terry Unterman - Regulatory Networks in Diabetes: Integrated Regulation of Hepatic Glucose and Lipid Metabolism by FoxO Proteins
February 9th: Jason Tsai (Bertozzi lab): Sensitive and multiplex quantification of anti-Islet cell antibodies for Type 1 Diabetes diagnostics and risk assessments
Dr. Anisha Patel: Examining Policies to Promote Access to Free Water in Schools as an Alternative to Sugar Sweetened Beverages
February 2nd: Monte Winslow: Genome Engineering in the Mouse Pancreas/Marina Basina: Managing Type 2 Diabetes: Where are we in 2018?
January 26th: Dr. Everett Meyer (Defining disease associated invariant NKT in human type 1 diabetes)/Dr. Paul Bollyky (IL-2 delivery and immune modulation in type 1 diabetes)
January 12th: Tom Soh (Technology for continuously measuring specific biomolecules in vivo)/Korey Hood (Science of Behavior: Opportunities to Optimize Diabetes Outcomes)
January 10, 2018: Invited guest speaker - Danny Chou, PhD Assistant Professor-University of Utah "Toward Optimal Insulin Action and Performance for People with Diabetes"